Article
Immunology
Hong Chen, Ke Wang, Tao Yuan, Xiaoming Wang, Lan Huanng, Zhenhuan Jiang, Keyang Chen, Yuejun Du
Summary: The study found that the dual bronchodilator is superior to ICS/LABA in improving lung function and is associated with a lower risk of pneumonia in COPD patients. However, there are no significant differences in other efficacy and safety profiles between these two maintenance treatments.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Rui Xu, Shi Feng, Zhou Ao, Yingxiang Chen, Congping Su, Xiuling Feng, Qin Fu, Xiaoyan Yang
Summary: Psoriasis is a chronic inflammatory disease that affects a significant portion of the population worldwide. Salmeterol, a long-acting beta(2)-AR agonist, alleviates the severity of psoriasis by inhibiting the proliferation and promoting apoptosis of keratinocytes.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Ben Jones, Vinod Burade, Elina Akalestou, Yusman Manchanda, Zenouska Ramchunder, Gaelle Carrat, Marie-Sophie Nguyen-Tu, Piero Marchetti, Lorenzo Piemonti, Isabelle Leclerc, Rajamannar Thennati, Tina Vilsboll, Bernard Thorens, Alejandra Tomas, Guy A. Rutter
Summary: This study describes the in vitro characteristics and antidiabetic efficacy of GL0034, a novel GLP-1RA. GL0034 showed increased binding affinity and bias towards cAMP signaling compared to semaglutide. In vivo studies in mice demonstrated that GL0034 had powerful antidiabetic effects, including weight loss and improved glycemic control.
DIABETES OBESITY & METABOLISM
(2022)
Article
Multidisciplinary Sciences
Eung Gu Lee, Youlim Kim, Yong Il Hwang, Kwang Ha Yoo, So Eun Lee, Kyung Yoon Jung, Doik Lee, Yong Bum Park, Chin Kook Rhee
Summary: This study compared the incidence of pneumonia in patients with chronic obstructive pulmonary disease (COPD) treated with long-acting muscarinic antagonists (LAMA) versus inhaled corticosteroids and long-acting beta(2)-agonist (ICS/LABA). The study found that patients on ICS had a higher incidence of pneumonia compared to those on LAMA. The use of ICS should be avoided in COPD patients at high risk for pneumonia.
SCIENTIFIC REPORTS
(2023)
Review
Multidisciplinary Sciences
Ting Liu, Dan Yang, Chuntao Liu
Summary: The study compared the clinical effects of extrafine HFA-BDP-F and nonextrafine ICS-LABA in treating asthma, finding no significant differences in improving pulmonary function, controlling asthma symptoms, reducing exacerbations, and improving lung deposition.
Article
Allergy
Helen Kathryn Reddel, Guy Brusselle, Rosa Lamarca, Per Gustafson, Gary P. Anderson, Carin Jorup
Summary: This study aimed to evaluate the safety and effectiveness of as needed formoterol in patients taking maintenance ICS-formoterol or ICS-salmeterol. The results showed that as-needed formoterol significantly reduced exacerbation risk in patients on maintenance ICS-formoterol but not in patients on maintenance ICS-salmeterol.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Sport Sciences
Jan S. Jeppesen, Soren Jessen, Martin Thomassen, Vibeke Backer, Jens Bangsbo, Morten Hostrup
Summary: This study found that an inhaled one-off dose of 54 μg formoterol has a performance-enhancing potential on sprint ability and short intense performance in elite male cyclists. This enhancing effect is irrespective of training status but partly related to muscle fiber type distribution for sprint ability.
SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS
(2023)
Article
Pharmacology & Pharmacy
Helene Salvator, Emmanuel Naline, Marion Brollo, Hermann Tenor, Stanislas Grassin-Delyle, Philippe Devillier
Summary: The study found that roflumilast N-oxide and roflumilast could cause slight relaxation in human bronchi at a specific concentration, and their combination with the long-acting beta(2)-agonist formoterol resulted in a more potent bronchodilation effect. However, at clinically relevant concentrations, these phosphodiesterase 4 inhibitors were not effective as direct bronchodilators.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2021)
Article
Cell Biology
Olivier Benichou, Tamer Coskun, Malgorzata D. Gonciarz, Parag Garhyan, Andrew C. Adams, Yu Du, James D. Dunbar, Jennifer A. Martin, Kieren J. Mather, Richard T. Pickard, Vincent L. Reynolds, Deborah A. Robins, Simbarashe P. Zvada, Paul J. Emmerson
Summary: GDF15 and its receptor GFRAL/RET have a role in regulating food intake and body weight. A GDF15 analog, LY3463251, is a potent agonist at the GFRAL/RET receptor with prolonged pharmacokinetics. In preclinical and clinical studies, LY3463251 reduces food intake and body weight, although the weight loss is modest and there are side effects of nausea and emesis.
Article
Pharmacology & Pharmacy
Mahmoud M. Mostafa, Christopher F. Rider, N. Dulmini Wathugala, Richard Leigh, Mark A. Giembycz, Robert Newton
Summary: In 2019, asthma treatment guidelines recommended ICS/LABA combination therapy as a first-line treatment option. The study found that formoterol and budesonide induced gene expression changes in BEAS-2B and pHBECs cells, with the combination of both drugs leading to more gene induction and repression compared to individual treatments.
MOLECULAR PHARMACOLOGY
(2021)
Article
Critical Care Medicine
Meng-Ting Wang, Jyun-Heng Lai, Ya-Ling Huang, Jun-Ting Liou, Shih-Hsuan Cheng, Chen Wei Lin, Hsueh-Yi Pan, Yu-Juei Hsu, Chen-Liang Tsai
Summary: In this study, the comparative effectiveness and safety of LABA/LAMA and LABA/ICS FDCs in COPD patients were investigated using Taiwanese nationwide health care claims. Indacaterol plus glycopyrronium (IND/GLY) and vilanterol plus umeclidinium (VI/UMEC) were found to be associated with lower exacerbation rates and pneumonia risks compared to salmeterol plus fluticasone propionate (SAL/FP). However, no significant differences were observed between LABA/LAMA FDCs.
Article
Respiratory System
Yechan Kim, Vincent Hou, Ryan D. Huff, Jennifer A. Aguiar, Spencer Revill, Nicholas Tiessen, Quynh Cao, Matthew S. Miller, Mark D. Inman, Kjetil Ask, Andrew C. Doxey, Jeremy A. Hirota
Summary: The study suggests that modulating intracellular cAMP levels by inhibiting phosphodiesterase 4 (PDE4) or blocking ATP Binding Cassette Transporter C4 (ABCC4) can enhance the efficacy of LABA/GCS therapy in asthma when challenged with viral stimuli.
RESPIRATORY RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Collin Vandemark, Jimmy Nguyen, Zhi-Qing Zhao
Summary: This review provides an overview of the cardiovascular protection from liraglutide against the deleterious effects of Ang II and pressure overload on the heart, based on our recent experimental studies. The mechanisms underlying liraglutide's inhibition of oxidative stress, vascular endothelial dysfunction, hypertension, cardiac fibrosis, left ventricular hypertrophy, and heart failure are addressed. Therefore, liraglutide continues to be a useful add-on therapy for the management of cardiovascular diseases.
Article
Physiology
Akira Umeda, Hisato Shimada, Tateki Yamane, Taichi Mochizuki, Yasushi Inoue, Kenji Tsushima, Kazuya Miyagawa, Atsumi Mochida, Hiroshi Takeda, Yasumasa Okada, Katsunori Masaki, Masako Matsusaka, Koichi Fukunaga
Summary: The study investigated the real-world effects of once-daily inhaled corticosteroid fluticasone furoate (FF) combined with a long-acting beta-2 agonist vilanterol (VI) and a long-acting muscarinic antagonist umeclidinium (UMEC) on lung function tests in asthma patients. The results showed that FF/UMEC/VI significantly improved forced expiratory volume, peak flow, and asthma control test score. Compared to FF/VI treatment, FF/UMEC/VI also showed improvement in certain lung function parameters. Overall, the study demonstrated the effectiveness of once-daily FF/UMEC/VI in treating asthma without serious adverse effects.
FRONTIERS IN PHYSIOLOGY
(2023)
Review
Respiratory System
Ji'an Zhou, Jing Zhang, Min Zhou, Jingqing Hang, Min Zhang, Fengfeng Han, Huili Zhu
Summary: Recommendations for COPD management in China include adopting a clinical pathway that considers clinical characteristics and classifying phenotypic characteristics of COPD for improved quality of life. LAMA/LABA fixed-dose combinations are a suitable choice for symptom relief.
JOURNAL OF THORACIC DISEASE
(2021)